This study aims to evaluate the effectiveness of \[18F\]-DPA-714 PET imaging in detecting neuroimmune activity in patients with autoimmune encephalitis (AE). The primary objective is to compare \[18F\]-DPA-714 binding in AE patients to healthy controls.
Age 18-80 years;
meeting clinical criteria for "possible" AE with identified antibodies;
newly diagnosed with symptoms <6 months;
no second-line immunosuppressive treatment;
Pregnant women;
contraindications to MRI;
known allergic reaction to [18F]-DPA-714; legal protection measure;
paraneoplastic syndrome following immune checkpoint inhibitor therapy.
Parallel
TEP with radioligand EAI 714
Other intervention60-minutes \[18F\]-DPA-714 PET imaging
binding potential (BP) in AE patients
Whole-brain \[18F\]-DPA-714 binding potential (BP) in AE patients compared to healthy controls.
Click on the lead sponsor to view all of their trials.
